Scarica l'app Stockscreener
19.28
2.68%
-0.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.81
Aprire:
$19.71
Volume 24 ore:
934.85K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.37B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-9.2249
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
-4.98%
1M Prestazione:
-11.36%
6M Prestazione:
-54.58%
1 anno Prestazione:
-45.55%
Intervallo 1D:
$18.87
$19.71
Intervallo di 1 settimana:
$18.87
$21.15
Portata 52W:
$17.64
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
19.28 | 1.37B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Artificial Pancreas Device System Market Projected To Witness - openPR
Tandem Diabetes Care Insiders Sell US$1.5m Of Stock, Possibly Signalling Caution - Simply Wall St
Tandem Diabetes Care Inc (TNDM) Stock Price Down 4.6% on Mar 26 - GuruFocus.com
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - Yahoo Finance
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology - MSN
Stifel maintains Tandem Diabetes Care stock Buy rating, $60 target By Investing.com - Investing.com UK
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights - Investing.com
Tandem Diabetes at Oppenheimer Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Tandem announces publication of results from trial of Control-IQ+ AID technology - Yahoo Finance
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - Yahoo Finance
Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D - BioWorld Online
Tandem reports A1C reduction in type 2 diabetes study By Investing.com - Investing.com South Africa
Tandem Diabetes Launches Next-Gen Automated Insulin Delivery Algorithm in U.S. - MPO-mag
Tandem reports A1C reduction in type 2 diabetes study - Investing.com India
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
Automated Insulin Delivery System Helps in Type 2 Diabetes - Medscape
Tubeless Insulin Pump Market Is Booming Worldwide | Medtronic - openPR
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery technology in the US - Marketscreener.com
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Enid News & Eagle
3 Healthcare Stocks Walking a Fine Line - Yahoo Finance
Artificial Pancreas (Closed-Loop Insulin Delivery) Market - openPR
Tandem Diabetes Care (NASDAQ:TNDM) Trading Up 6.1% Following Insider Buying Activity - Defense World
Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings - MSN
Tandem Diabetes at Leerink Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com UK
Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Bank of New York Mellon Corp Purchases 4,130 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes Care’s SWOT analysis: stock outlook amid market challenges - Investing.com
Keybank National Association OH Has $245,000 Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes EVP Kyrillos purchases $190,966 in company stock By Investing.com - Investing.com South Africa
Tandem Diabetes EVP Kyrillos purchases $190,966 in company stock - Investing.com
Reasons to Hold TNDM Stock in Your Portfolio for Now - Nasdaq
Tandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation Opportunity - TipRanks
Smartleaf Asset Management LLC Acquires 1,101 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - Defense World
Tandem Diabetes Care, Inc. to Host Earnings Call - ACCESS Newswire
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by US Bancorp DE - Defense World
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oppenheimer & Co. Inc. - Defense World
TANDEM DIABETES CARE, INC. (NASDAQ:TNDM) DEADLINE ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. - ACCESS Newswire
Tandem Diabetes Care stock hits 52-week low at $18.27 By Investing.com - Investing.com Australia
Tandem Diabetes Care stock hits 52-week low at $18.27 - Investing.com
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Position Increased by Private Advisor Group LLC - Defense World
Morgan Stanley Downgrades Tandem Diabetes Care (NASDAQ:TNDM) to Equal Weight - Defense World
Tandem Diabetes Care (NASDAQ:TNDM) Rating Lowered to Neutral at Citigroup - Defense World
Morgan Stanley Downgrades Tandem Diabetes Care (TNDM) - MSN
Tandem Diabetes Care downgraded to Equal-weight on guidance concerns - MSN
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):